Carteolol 是一种非选择性 β-肾上腺素受体拮抗剂 (β-adrenoceptor)。Carteolol 通过半胱天冬酶激活和线粒体依赖性途径诱导细胞凋亡。Carteolol 可用于青光眼研究。
| 生物活性 | Carteolol is a non-selectiveβ-adrenoceptorantagonist. Carteolol inducesapoptosisvia acaspaseactivated and mitochondrial-dependent pathway. Carteolol can be used for glaucoma research[1]. |
体外研究
(In Vitro) | Carteolol (0-2%; 0-28 hours; HCECs) has cytotoxicity and decreases cell viability in a dose- and time-dependent manner[1].
Carteolol (0.25%; 4-12 hours; HCECs) induces apoptosis and necroptotic protein expression in HCECs[1].
Cell Viability Assay[1] | Cell Line: | HCECs | | Concentration: | 0.00390625-2% | | Incubation Time: | 0, 2, 4, 8, 16, 20,24 and 28 hours | | Result: | Decreased cell viability with the concentrations above 0.0015625% in a dose- and time-dependent manner. |
Western Blot Analysis[1] | Cell Line: | HCECs | | Concentration: | 0.25% | | Incubation Time: | 4, 8 and 12 hours | | Result: | Dampened expression of the anti-apoptotic protein Bcl-2 and Bcl-xL, enhanced expression of the pro-apoptotic proteins Bax and Bad, and mitochondrial-released pro-apoptotic proteins Cyt.c and AIF. |
Cell Cycle Analysis[1] | Cell Line: | HCECs | | Concentration: | 0.25% | | Incubation Time: | 4, 8 and 12 hours | | Result: | Increased the number of G1 phase of the cell cycle, whereas decreased S phase. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com